NasdaqGS:INSMBiotechs
Insmed (INSM) Reports 12 Month TPIP Data That Sets Up Phase 3
Insmed reported positive 12 month open label extension data for TPIP in pulmonary arterial hypertension.
The study showed sustained improvements in six minute walk distance and NT proBNP, with no new safety signals reported.
These results support Insmed’s plan to advance TPIP into a Phase 3 randomized, controlled trial.
For investors tracking Insmed, ticker NasdaqGS:INSM, the TPIP update adds a fresh data point to a stock that has moved sharply over multi year periods, with a very large 3...